Jci_page_head_homepage_01 Jci_page_head_homepage_02
Vissia Viglietta, Sally C. Kent, Tihamer Orban, David A. Hafler
Published in Volume 109, Issue 7
J Clin Invest. 2002; 109(7):895–903 doi:10.1172/JCI14114
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Proliferative response to GAD65 is not dependent on CD28/B7 co-stimulatory pathway in type 1 diabetes patients. The mean percentage of inhibition of GAD65-specific proliferation and cytokine secretion with CD28 blockade, as described in Figure 1, is shown. Each symbol is representative of ten diabetic patients (open circles) or nine normal controls (filled circles). The Mann-Whitney test was used to estimate the difference in the CD28 requirement between diabetic patients and controls. The difference between the two groups was significant at any concentration of GAD65 (diabetic patients vs. controls, proliferation: GAD, 5 μg/ml and 10 μg/ml, P = 0.0019; GAD 20 μg/ml, P = 0.0047; IFN-γ: GAD 5 μg/ml, P = 0.049; GAD 10 μg/ml, P = 0.0019; GAD 20 μg/ml, P = 0.001; IL-13: GAD 5 μg/ml, P = 0.049; GAD 10 μg/ml, P = 0.03; GAD 20 μg/ml, P = 0.0019) showing that antigen-specific T cells from type 1 diabetes patients are CD28 independent. No inhibition was detected in TT-specific T cells at any concentration of antigen either in the patients or in the normal controls.